CYTK vs. RNA, CNST, ZGNX, ICPT, PHAT, ALNY, GMAB, TEVA, RPRX, and BGNE
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Avidity Biosciences (RNA), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Intercept Pharmaceuticals (ICPT), Phathom Pharmaceuticals (PHAT), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), and BeiGene (BGNE).
Cytokinetics (NASDAQ:CYTK) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Cytokinetics received 644 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 79.29% of users gave Cytokinetics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Cytokinetics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Avidity Biosciences has a net margin of -2,103.78% compared to Cytokinetics' net margin of -14,141.74%. Cytokinetics' return on equity of 0.00% beat Avidity Biosciences' return on equity.
In the previous week, Cytokinetics had 18 more articles in the media than Avidity Biosciences. MarketBeat recorded 25 mentions for Cytokinetics and 7 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.03 beat Cytokinetics' score of 0.35 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Avidity Biosciences has higher revenue and earnings than Cytokinetics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Cytokinetics currently has a consensus target price of $74.88, suggesting a potential upside of 54.36%. Avidity Biosciences has a consensus target price of $41.33, suggesting a potential upside of 53.88%. Given Cytokinetics' higher probable upside, equities research analysts plainly believe Cytokinetics is more favorable than Avidity Biosciences.
Summary
Cytokinetics and Avidity Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
